Cargando…

Let-7i Reduces Aggressive Phenotype and Induces BRCAness in Ovarian Cancer Cells

SIMPLE SUMMARY: Ovarian cancer has a dismal prognosis and innovative treatment options are necessary to improve survival. Because the microRNA let-7 is often lost in this and other cancers, and its loss is associated with poor prognosis, we focused on therapeutic strategies to replace it. We report...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chirshev, Evgeny, Suzuki, Tise, Wang, Hanmin, Nguyen, Anthony, Hojo, Nozomi, Sanderman, Linda, Mirshahidi, Saied, Ioffe, Yevgeniya J., Unternaehrer, Juli J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468164/ https://www.ncbi.nlm.nih.gov/pubmed/34572843 http://dx.doi.org/10.3390/cancers13184617

Ejemplares similares

Epithelial/mesenchymal heterogeneity of high‐grade serous ovarian carcinoma samples correlates with miRNA let‐7 levels and predicts tumor growth and metastasis
por: Chirshev, Evgeny, et al.
Publicado: (2020)

The Epithelial–Mesenchymal Transcription Factor SNAI1 Represses Transcription of the Tumor Suppressor miRNA let-7 in Cancer
por: Wang, Hanmin, et al.
Publicado: (2021)

Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer
por: Chirshev, Evgeny, et al.
Publicado: (2019)

Role of epithelial-mesenchymal transition factor SNAI1 and its targets in ovarian cancer aggressiveness
por: Suzuki, Tise, et al.
Publicado: (2023)

Snail knockdown reverses stemness and inhibits tumour growth in ovarian cancer
por: Hojo, N., et al.
Publicado: (2018)

Racial and Ethnic Disparities in Gynecologic Carcinosarcoma: A Single-Institution Experience
por: Mercado, Kristina E., et al.
Publicado: (2023)

Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge
por: Caeiro, Cláudia, et al.
Publicado: (2022)

BRCAness in prostate cancer
por: Bednarz-Knoll, Natalia, et al.
Publicado: (2019)

The BRCAness Landscape of Cancer
por: Guo, Maoni, et al.
Publicado: (2022)

BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence
por: Wysham, Weiya Z., et al.
Publicado: (2012)

AURKA inhibition mimics BRCAness
por: Hirst, Jeff, et al.
Publicado: (2017)

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
por: Tsyganov, Matvey Mihajlovich, et al.
Publicado: (2022)

Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness
por: Thompson, Timothy C., et al.
Publicado: (2017)

BRCAness as a prognostic indicator in patients with early breast cancer
por: Liu, Lei, et al.
Publicado: (2020)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
por: Xavier, Mary-Ann, et al.
Publicado: (2021)

TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity
por: Liu, Qizhi, et al.
Publicado: (2022)

Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness
por: Darbeheshti, Farzaneh, et al.
Publicado: (2022)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness
por: Tutt, A
Publicado: (2018)

Development of a novel BRCAness score that predicts response to PARP inhibitors
por: Oshi, Masanori, et al.
Publicado: (2022)

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
por: Holme, Harriett, et al.
Publicado: (2018)

Detection of bone metastases in uterine cancer: How common are they and should PET/CT be the standard for diagnosis?
por: Hong, Linda, et al.
Publicado: (2021)

A case of niraparib PARP-Inhibitor induced Sweet Syndrome in gynecologic cancer
por: Badiner, Nora, et al.
Publicado: (2023)

The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
por: Morra, Francesco, et al.
Publicado: (2022)

Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype
por: Jeong, Keun-Yeong, et al.
Publicado: (2021)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer
por: Lin, Po‐Han, et al.
Publicado: (2020)

DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma
por: Barenboim, Maxim, et al.
Publicado: (2021)

Searching for the source: Extraovarian primary peritoneal carcinoma presenting as chest wall masses
por: Brinker Feng, Madison, et al.
Publicado: (2023)

A Novel Insertion Mutation on Exon 20 of Epidermal Growth Factor Receptor, Conferring Resistance to Erlotinib
por: Khan, Nawazish A., et al.
Publicado: (2014)

miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype
por: Tommasi, Stefania, et al.
Publicado: (2016)

Let Us Aggressively Confront the Coronavirus Pandemic
por: Somberg, John
Publicado: (2020)

Glucocorticoid Receptor Regulates and Interacts with LEDGF/p75 to Promote Docetaxel Resistance in Prostate Cancer Cells
por: Sanchez-Hernandez, Evelyn S., et al.
Publicado: (2023)

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
por: Holme, Harriett, et al.
Publicado: (2018)

Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample
por: Yoshida, Reiko, et al.
Publicado: (2021)

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
por: Lips, E H, et al.
Publicado: (2013)

MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma
por: Liu, Qi, et al.
Publicado: (2021)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors
por: Zhang, Chao, et al.
Publicado: (2023)

Pharmacological ascorbate induces ‘BRCAness’ and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer
por: Ma, Yan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_da52r491sk5qhqqr073annh22u